

Government Gazette
Staatskoerant

REPUBLIC OF SOUTH AFRICA
REPUBLIEK VAN SUID AFRIKA

Regulation Gazette **No. 11213** *Regulasiekoerant*

Vol. 666 **18 December / Desember 2020** **No. 44019**

N.B. The Government Printing Works will not be held responsible for the quality of "Hard Copies" or "Electronic Files" submitted for publication purposes

ISSN 1682-5843

9 771682 584003 44019



AIDS HELPLINE: 0800-0123-22 Prevention is the cure

IMPORTANT NOTICE:

THE GOVERNMENT PRINTING WORKS WILL NOT BE HELD RESPONSIBLE FOR ANY ERRORS THAT MIGHT OCCUR DUE TO THE SUBMISSION OF INCOMPLETE / INCORRECT / ILLEGIBLE COPY.

NO FUTURE QUERIES WILL BE HANDLED IN CONNECTION WITH THE ABOVE.

Contents

No.		Gazette No.	Page No.
GOVERNMENT NOTICES • GOEWERMENTSKENNISGEWINGS			
Health, Department of/ Gesondheid, Departement van			
R. 1375	Medicines and Related Substances Act (101/1965): Schedules	44019	3

DEPARTMENT OF HEALTH

NO. R. 1375 **18 DECEMBER 2020**

MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT No. 101 OF 1965)
SCHEDULES

The Minister of Health has, in terms of section 22A(2) of the Medicines and Related Substances Act, 1965 (Act No. 101 of 1965), on the recommendation of the South African Health Products Regulatory Authority (SAHPRA), made and updated the Schedules.

This Schedule amends the Schedules as inserted by Government Notice R.509 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 24727, 10 April 2003; substituted by Government Notice R.935 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 31387, 5 September 2008; and amended by Government Notice R.1230 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 32838, 31 December 2009; Government Notice R.227 (Medicines and Related Substances Act: Schedules)in Government *Gazette* 35149, 15 March 2012; Government Notice R.674 (Medicines and Related Substances Act, 1965: Schedules) in Government Gazette 36827, 13 September 2013, Government Notice R.690 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 36850, 20 September 2013,Government Notice R.104 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 37318, 11 February 2014; Government Notice R.352 (Medicines and Related Substances Act, 1965: Schedules) in, Government *Gazette* 37622, 8 May 2014; Government Notice R.234 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 38586, 20 March 2015; Government Notice R.254 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 39815, 15 March 2016; Government Notice R.254 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 40041, 03 June 2016; Government Notice No.748 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 41009, 28 July 2017; Government Notice No.1261 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 41256, 17 November 2017; Government Notice No.1262 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 42052, 23 November 2018 and Government Notice No.755 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 42477, 23 May 2019; Government Notice No.R219 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 430151, 28 February 2020 and Government Notice No.R586 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 43347, 22 May 2020 using the following convention:

- Words in bold and in square brackets (e.g. **[Gamma benzene hexachloride]** in Schedule 1), indicate omission from a Schedule
- Words underlined with a solid line (e.g. Gamma benzene hexachloride), indicate insertions in a Schedule.

SCHEDULE

In these Schedules, "the Act" means the Medicines and Related Substances Act, 1965 (Act No.101 of 1965)

Note: Where an alternative schedule(s) is included in natural parentheses at any point of an inscription, this is provided to indicate one or more alternative scheduling designation/s. This is for information only and shall not be used in the interpretation of such inscription.

SCHEDULE 1

a. All substances referred to in this Schedule are excluded when specifically packed, labelled, sold and used for –
   (i) industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose; and
   (ii) analytical laboratory purposes.

b. All preparations of substances or mixtures of such substances containing or purporting to contain any substance referred to in this Schedule and includes the following:
   (i) The salts and esters of such substances, where the existence of such salts and esters is possible; and
   (ii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.

c. In terms of section 22A(4)(a)(v) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974 (Act No. 56 of 1974) other than a medical practitioner or dentist may prescribe and supply, only within his/her scope of practice and subject to the indication for use of such substances and medicines and to the conditions determined by the Authority, to patients under his/her care, the Schedule 1 substances and medicines provided for in the Annexures to this Schedule published in the *Gazette* in terms of the Act.

Schedule 1

(i)	Annexure 1A:	Emergency Care Provider (Paramedic);
	Annexure 1B:	Emergency Care Provider (Emergency Care Practitioner);
	Annexure 1C:	Basic Ambulance Assistant
	Annexure 1D:	Ambulance Emergency Assistant
	Annexure 1E:	Emergency Care Technician
	Annexure 1F:	Emergency Care Assistant
(ii)	Annexure 2:	Dental Therapist;
(iii)	Annexure 3:	Optometrist.
(iv)	Annexure 4:	Podiatrist

Arsenic;

a. in oral dosage forms in concentrations equivalent to 0,01 percent or less of arsenic trioxide; (S2)

b. except when intended for injection. (S4)

Benzydamine,

a. preparations and mixtures containing **[0,15 percent or less of benzydamine, when]** intended for use as a mouth rinse or for topical application in the mouth and throat; provided that the total dose swallowed does not exceed 36 milligrams of benzydamine per day. (S3)

b. except preparations and mixtures containing 3 percent or less of benzydamine, when intended for application to the skin (S0) **[(S3)]**; or

c. except preparations and mixtures containing 3 milligrams or less of benzydamine per throat lozenge: Provided that the total dose swallowed does not exceed 36 milligrams of benzydamine per day and the pack size does not exceed 16 lozenges. (S0)

d. except when indicated for human vaginal use. (S2)

Flurbiprofen,

a. when in the form of lozenges, indicated for the relief of pain associated with sore throats, subject to:
   (i) a maximum of 8,75 milligrams per lozenge;
   (ii) a maximum treatment period of 3 days; and
   (iii) a maximum pack size of 15 lozenges. (S3)

b. except when intended for application to the skin and indicated for the symptomatic relief of localised pain and inflammation, provided that in the case of application by transdermal patch:
   (i) use is restricted to adults and children 12 years and older; and
   (ii) the treatment period is limited to a maximum of 4 weeks (S0)

c. except when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days; (S2)

d. except when intended for ophthalmic use. (S4)

ANNEXURE 1A: EMERGENCY CARE PROVIDER (PARAMEDIC)

PARAMEDIC (National Diploma in Emergency Medical Care graduates ***only***) registered with Health Professions Council of South Africa

PARAMEDIC (National Diploma in Emergency Medical Care graduates ***only***)
WATER Substance : Water for injection Indication : Diluent Route of Administration : Parenteral
WATER Substance : Water for irrigation Indication : Wound and dressing irrigation Route of Administration : Solution

ANNEXURE 1B: EMERGENCY CARE PROVIDER (EMERGENCY CARE PRACTITIONER)

EMERGENCY CARE PRACTITIONER (Bachelor of Technology Degree in Emergency Medical Care) registered with Health Professions Council of South Africa

EMERGENCY CARE PRACTITIONER (B Tech: Emergency Medical Care)
WATER Substance : Water for injection Indication : Diluent Route of Administration : Parenteral
WATER Substance : Water for irrigation Indication : Wound and dressing irrigation Route of Administration : Solution

Schedule 1

ANNEXURE 1C: BASIC AMBULANCE ASSISTANT

BASIC AMBULANCE ASSISTANT registered with Health Professions Council of South Africa

BASIC AMBULANCE ASSISTANT registered with Health Professions Council of South Africa	
WATER	
Substance	: Water for injection
Indication	: Diluent
Route of Administration	: Parenteral
WATER	
Substance	: Water for irrigation
Indication	: Wound and dressing irrigation
Route of Administration	: Solution

ANNEXURE 1D: AMBULANCE EMERGENCY ASSISTANT

AMBULANCE EMERGENCY ASSISTANT registered with Health Professions Council of South Africa

AMBULANCE EMERGENCY ASSISTANT registered with Health Professions Council of South Africa	
WATER	
Substance	: Water for injection
Indication	: Diluent
Route of Administration	: Parenteral
WATER	
Substance	: Water for irrigation
Indication	: Wound and dressing irrigation
Route of Administration	: Solution

ANNEXURE 1E: EMERGENCY CARE TECHNICIAN

EMERGENCY CARE TECHNICIAN registered with Health Professions Council of South Africa

EMERGENCY CARE TECHNICIAN registered with Health Professions Council of South Africa	
WATER	
Substance	: Water for injection
Indication	: Diluent
Route of Administration	: Parenteral
WATER	
Substance	: Water for irrigation

Schedule 1

EMERGENCY CARE TECHNICIAN registered with Health Professions Council of South Africa	
Indication	: Wound and dressing irrigation
Route of Administration	: Solution

ANNEXURE 1F: EMERGENCY CARE ASSISTANT

EMERGENCY CARE ASSISTANT registered with Health Professions Council of South Africa

EMERGENCY CARE ASSISTANT registered with Health Professions Council of South Africa	
WATER	
Substance	: Water for injection
Indication	: Diluent
Route of Administration	: Parenteral
WATER	
Substance	: Water for irrigation
Indication	: Wound and dressing irrigation
Route of Administration	: Solution

ANNEXURE 4: PODIATRIST

PODIATRIST [(B.Tech degree in Podiatry)] registered with the Health Professions Council of South Africa in terms of the Health Professions Act, 1974 (Act 56 of 1974)

– END SCHEDULE 1 –

SCHEDULE 2

a. All substances referred to in this Schedule are excluded when specifically packed, labeled, sold and used for –

(i) industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose; and

(ii) analytical laboratory purposes.

b. All preparations of substances or mixtures of such substances containing or purporting to contain any substance referred to in this Schedule and includes the following:

(i) The salts and esters of such substances, where the existence of such salts and esters is possible; and

(ii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.

c. In terms of section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974 (Act 56 of 1974) other than a medical practitioner or dentist may prescribe and supply, only within their scope of practice and subject to the indication for use of such substances and medicines and to the conditions determined by the Authority, to patients under his/her care, the Schedule 2 substances and medicines provided for in the Annexures to this Schedule published in the Gazette in terms of the Act.

(i)	Annexure 1A:	Emergency Care Provider (Paramedic);
	Annexure 1B:	Emergency Care Provider (Emergency Care Practitioner);
	Annexure 1C:	Basic Ambulance Assistant
	Annexure 1D:	Ambulance Emergency Assistant
	Annexure 1E:	Emergency Care Technician
	Annexure 1F:	Emergency Care Assistant
(ii)	Annexure 2:	Dental Therapist;
(iii)	Annexure 3:	Optometrist.
(iv)	Annexure 4:	Podiatrist

Arsenic;

a. except **[preparations]** in oral dosage forms containing the equivalent of 0,01 percent or less of arsenic trioxide; (S1)

b. except when intended for injection. (S4)

Benzydamine,

a. when intended for use human vaginal use; (S3)

Schedule 2

b. except preparations and mixtures containing 3 percent or less of benzydamine, when intended for application to the skin; (S0)

c. except preparations and mixtures intended for use as a mouth rinse or for topical application in the mouth and throat; provided that the total dose swallowed does not exceed 36 milligrams of benzydamine per day; (S1)

d. except preparations and mixtures containing 3 milligrams or less of benzydamine per throat lozenge; Provided that the total dose swallowed does not exceed 36 milligrams of benzydamine per day and the pack size does not exceed 16 lozenges. (S0)"

Clonidine when intended for the **[treatment]** prevention of migraine. (S3)

Doxycycline,

a. when intended and labelled for the chemoprophylaxis of malaria in those aged 8 years and older **[for periods not exceeding 4 months of continuous use]**. (S4)

Flurbiprofen,

a. when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days;(S3)
b. except when in the form of lozenges, indicated for the relief of pain associated with sore throats, subject to:
   (i) a maximum of 8,75 milligrams per lozenge;
   (ii) a maximum treatment period of 3 days; and
   (iii)a maximum pack size of 15 lozenges. (S1)
c. except when intended for application to the skin and indicated for the symptomatic relief of localised pain and inflammation, provided that in the case of application by transdermal patch:
   (i) use is restricted to adults and children 12 years and older; and
   (ii) the treatment period is limited to a maximum of 4 weeks **[S1]** (S0)
d. except when intended for ophthalmic use. (S4)

olopatidine.

Schedule 2

ANNEXURE 1A: EMERGENCY CARE PROVIDER (PARAMEDIC)

PARAMEDIC (National Diploma in Emergency Medical Care graduates ***only***) registered with Health Professions Council of South Africa

PARAMEDIC(National Diploma in Emergency Medical Care graduates *only*)		
SELECTIVE β2 AGONISTS		
Substance	:	Salbutamol
Indication	:	Bronchodilator
Route of Administration	:	Aerosol
NON-STEROIDAL ANTI-INFLAMMATORY		
Substance	:	Ibuprofen
Indication	:	Analgesic/ Anti-inflammatory
Route of Administration	:	Oral
ANALGESIC		
Substance	:	Paracetamol
Indication	:	Analgesic/ Anti-pyrexia
Route of Administration	:	Oral

ANNEXURE 1B: EMERGENCY CARE PROVIDER (EMERGENCY CARE PRACTITIONER)

EMERGENCY CARE PRACTITIONER

(Bachelor of Technology Degree in Emergency Medical Care) registered with Health Professions Council of South Africa

EMERGENCY CARE PRACTITIONER (B Tech: Emergency Medical Care)		
SELECTIVE β2 AGONISTS		
Substance	:	Salbutamol
Indication	:	Bronchodilator
Route of Administration	:	Aerosol
ANTI-SPASMODIC		
Substance	:	Hyoscine butylbromide
Indication	:	Anti-spasmodic
Route of Administration	:	Oral
ANTI-PROPULSIVE		
Substance	:	Loperamide
Indication	:	Symptomatic management of diarrhoea in adults
Route of Administration	:	Oral

Schedule 2

EMERGENCY CARE PRACTITIONER (B Tech: Emergency Medical Care)		
NON-STEROIDAL ANTI-INFLAMMATORY		
Substance	:	Ibuprofen
Indication	:	Analgesic/ Anti-inflammatory
Route of Administration	:	Oral
ANALGESIC		
Substance	:	Paracetamol
Indication	:	Analgesic/ Anti-pyrexia
Route of Administration	:	Oral

ANNEXURE 1C: BASIC AMBULANCE ASSISTANT

BASIC AMBULANCE ASSISTANT registered with Health Professions Council of South Africa

BASIC AMBULANCE ASSISTANT registered with Health Professions Council of South Africa		
*ANTI-CHOLINERGIC		
Substance	:	Ipratropium bromide
Indication	:	Inhalant Bronchodilator (atropine derivative anti-cholinergic)
Route of Administration	:	Respirator Solution
*SELECTIVE β2 AGONISTS		
Substance	:	Salbutamol
Indication	:	Bronchodilator
Route of Administration	:	Aerosol

ANNEXURE 1D: AMBULANCE EMERGENCY ASSISTANT

AMBULANCE EMERGENCY ASSISTANT registered with Health Professions Council of South Africa

AMBULANCE EMERGENCY ASSISTANT registered with Health Professions Council of South Africa		
ANTI-CHOLINERGIC		
Substance	:	Ipratropium bromide
Indication	:	Inhalant Bronchodilator (atropine derivative anti-cholinergic)
Route of Administration	:	Respirator Solution
SELECTIVE β2 AGONISTS		
Substance	:	Salbutamol
Indication	:	Bronchodilator
Route of Administration	:	Aerosol

Schedule 2

ANNEXURE 1E: EMERGENCY CARE TECHNICIAN

EMERGENCY CARE TECHNICIAN registered with Health Professions Council of South Africa

EMERGENCY CARE TECHNICIAN registered with Health Professions Council of South Africa		
ANTI-CHOLINERGIC		
Substance	:	Ipratropium bromide
Indication	:	Inhalant Bronchodilator (atropine derivative anti-cholinergic)
Route of Administration	:	Respirator Solution
SELECTIVE β2 AGONISTS		
Substance	:	Salbutamol
Indication	:	Bronchodilator
Route of Administration	:	Aerosol

ANNEXURE 1F: EMERGENCY CARE ASSISTANT

EMERGENCY CARE ASSISTANT registered with Health Professions Council of South Africa

EMERGENCY CARE ASSISTANT registered with Health Professions Council of South Africa		
ANTI-CHOLINERGIC		
Substance	:	Ipratropium bromide
Indication	:	Inhalant Bronchodilator (atropine derivative anti-cholinergic)
Route of Administration	:	Respirator Solution
SELECTIVE β2 AGONISTS		
Substance	:	Salbutamol
Indication	:	Bronchodilator
Route of Administration	:	Aerosol

ANNEXURE 4: PODIATRIST

PODIATRIST [(B.Tech degree in Podiatry)] registered with the Health Professions Council of South Africa in terms of the Health Professions Act, 1974 (Act 56 of 1974)

– END SCHEDULE 2 –

SCHEDULE 3

a. All substances referred to in this Schedule are excluded when specifically packed, labelled, sold and used for –

(i) industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose; and

(ii) analytical laboratory purposes.

b. All preparations of substances or mixtures of such substances containing or purporting to contain any substance referred to in this Schedule and includes the following:

(i) The salts and esters of such substances, where the existence of such salts and esters is possible; and

(ii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.

c. In terms of section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974 (Act 56 of 1974) other than a medical practitioner or dentist may prescribe and supply, only within his/her scope of practice and subject to the indication for use of such substances and medicines and to the conditions determined by the Authority, to patients under his/her care, the Schedule 3 substances and medicines provided for in the Annexures to this Schedule published in the Gazette in terms of the Act.

(i)	Annexure 1A:	Emergency Care Provider (Paramedic);
	Annexure 1B:	Emergency Care Provider (Emergency Care Practitioner);
	Annexure 1C:	Basic Ambulance Assistant
	Annexure 1D:	Ambulance Emergency Assistant
	Annexure 1E:	Emergency Care Technician
	Annexure 1F:	Emergency Care Assistant
(ii)	Annexure 2:	Dental Therapist;
(iii)	Annexure 3:	Optometrist.
(iv)	Annexure 4:	Podiatrist

Benzydamine, except preparations and mixtures-

a. containing 3 percent or less of benzydamine, when intended for application to the skin; (S0) **[(S1)]**

b. **[containing 0,15 percent or less of benzydamine, when]** intended for use as a mouth rinse or for topical application in the mouth and throat; provided that the total dose swallowed does not exceed 36 milligrams of benzydamine per day; (S1)

Schedule 3

c. containing 3 milligrams or less of benzydamine per throat lozenge: Provided that the total dose swallowed does not exceed 36 milligrams of benzydamine per day and the pack size does not exceed 16 lozenges. (S0)"

d. intended for human vaginal use. (S2)

Clonidine except when intended for the **[treatment]** prevention of migraine. (S2)

Dexketoprofen trometamol.

(-)-6 epigallocatechin gallate

Flurbiprofen, except

a. when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days;(S3)

b. when in the form of lozenges, indicated for the relief of pain associated with sore throats, subject to:

(i). a maximum of 8,75 milligrams per lozenge;

(ii). a maximum treatment period of 3 days; and

(iii). a maximum pack size of 15 lozenges. (S1)

b. except when intended for application to the skin and indicated for the symptomatic relief of localised pain and inflammation, provided that in the case of application by transdermal patch:

(i) use is restricted to adults and children 12 years and older; and

(ii) the treatment period is limited to a maximum of 4 weeks. **[(S1)]** (S0)

c. when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days; (S2)

d. when intended for ophthalmic use; (S4)

Nicardipine.

Umeclidinium.

Schedule 3

ANNEXURE 1A: EMERGENCY CARE PROVIDER (PARAMEDIC)

PARAMEDIC (National Diploma in Emergency Medical Care graduates ***only***) registered with Health Professions Council of South Africa

PARAMEDIC (National Diploma in Emergency Medical Care graduates ***only***)
ANALGESIC Substance : Paracetamol Indication : Analgesic/ Anti-pyrexia Route of Administration : Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Ringers Lactate Indication : Plasma expanders Route of Administration : Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Polygeline Indication : Plasma expanders Route of Administration : Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Balanced Salt Solution Indication : Plasma expanders Route of Administration : Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Sodium Bicarbonate 8.5 % Indication : Metabolic acidosis Route of Administration : Parenteral

Schedule 3

ANNEXURE 1B: EMERGENCY CARE PROVIDER (EMERGENCY CARE PRACTITIONER)

EMERGENCY CARE PRACTITIONER

(Bachelor of Technology Degree in Emergency Medical Care) registered with Health Professions Council of South Africa

EMERGENCY CARE PRACTITIONER(B Tech: Emergency Medical Care)		
ANALGESIC		
Substance	:	Paracetamol
Indication	:	Analgesic/ Anti-pyrexia
Route of Administration	:	Parenteral
*ANTI-SPASMODIC		
Substance	:	Hyoscine butylbromide
Indication	:	Anti-spasmodic
Route of Administration	:	Parenteral
**ARTERIAL SMOOTH MUSCLE AGENT		
Substance	:	Hydralazine
Indication	:	Hypertension in pregnancy
Route of Administration	:	Oral
BETA BLOCKER		
Substance	:	Labetalol
Indication	:	Hypertension in pregnancy
Route of Administration	:	Parenteral
*CALCIUM CHANNEL BLOCKER		
Substance	:	Nifedipine
Indication	:	Hypertension in pregnancy
Route of Administration	:	Parenteral
**CLASS III ANTI-ARRHYTHMIC		
Substance	:	Sotalol
Indication	:	Anti-arrhythmic
Route of Administration	:	Oral/ Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Ringers Lactate
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Polygeline
Indication	:	Plasma expanders
Route of Administration	:	Parenteral

Schedule 3

EMERGENCY CARE PRACTITIONER(B Tech: Emergency Medical Care)		
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Balanced Salt Solution
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Sodium Bicarbonate 8,5 %
Indication	:	Metabolic acidosis
Route of Administration	:	Parenteral
**VASODILATOR		
Substance	:	Isosorbide dinitrate
Indication	:	Acute pulmonary syndrome/ Acute pulmonary oedema
Route of Administration	:	Parenteral

ANNEXURE 1C: BASIC AMBULANCE ASSISTANT

BASIC AMBULANCE ASSISTANT registered with Health Professions Council of South Africa

BASIC AMBULANCE ASSISTANT registered with Health Professions Council of South Africa		
*SELECTIVE β2 AGONISTS		
Substance	:	Salbutamol
Indication:	:	Bronchodilator
Route of Administration	:	Inhalant

ANNEXURE 1D: AMBULANCE EMERGENCY ASSISTANT

AMBULANCE EMERGENCY ASSISTANT registered with Health Professions Council of South Africa

AMBULANCE EMERGENCY ASSISTANT registered with Health Professions Council of South Africa		
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Dextran
Indication	:	Plasma expanders
Route of Administration	:	Parenteral

Schedule 3

PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Hydroxyethyl Starch
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Sodium chloride
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Ringers Lactate
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Polygeline
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Balanced Salt Solution
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Sodium Bicarbonate 8,5 %
Indication	:	Metabolic acidosis
Route of Administration	:	Parenteral
*CARBOHYDRATES		
Substance	:	Dextrose
Indication	:	Nutrition / Acute Symptomatic Hypoglycaemic Treatment in adults and paediatrics
Route of Administration	:	Parenteral
*CO-ENZYME		
Substance	:	Thiamine (Vitamin B1)
Indication	:	Nutritional supplement/ Vitamin B (Emergency treatment of Wernicke's encephalopathy and Beriberi)
Route of Administration	:	Parenteral
*OTHER MINERAL SUPPLEMENTS		
Substance	:	Magnesium sulphate
Indication	:	Mineral supplement; prevention and control of seizures and hypertension in toxaemia of pregnancy
Route of Administration	:	Parenteral

Schedule 3

SELECTIVE β2 AGONISTS		
Substance	:	Salbutamol
Indication:	:	Bronchodilator
Route of Administration	:	Inhalant

ANNEXURE 1E: EMERGENCY CARE TECHNICIAN

EMERGENCY CARE TECHNICIAN registered with Health Professions Council of South Africa

EMERGENCY CARE TECHNICIAN registered with Health Professions Council of South Africa		
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Dextran
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Hydroxyethyl Starch
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Sodium chloride
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Ringers Lactate
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Polygeline
Indication	:	Plasma expanders
Route of Administration	:	Parenteral

Schedule 3

PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Balanced Salt Solution
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Sodium Bicarbonate 8,5 %
Indication	:	Metabolic acidosis
Route of Administration	:	Parenteral
CARBOHYDRATES		
Substance	:	Dextrose
Indication	:	Nutrition / Acute Symptomatic Hypoglycaemic Treatment in adults and paediatrics
Route of Administration	:	Parenteral
*CO-ENZYME		
Substance	:	Thiamine (Vitamin B1)
Indication	:	Nutritional supplement/ Vitamin B (Emergency treatment of Wernicke's encephalopathy and Beriberi)
Route of Administration	:	Parenteral
OTHER MINERAL SUPPLEMENTS		
Substance	:	Magnesium sulphate
Indication	:	Mineral supplement; prevention and control of seizures and hypertension in toxaemia of pregnancy. Ventricular anti-arrhythmic
Route of Administration	:	Parenteral
ORGANIC NITRATES		
Substance	:	Glyceryl trinitrate
Indication	:	Vasodilator
Route of Administration	:	Oral
SELECTIVE ß2 AGONISTS		
Substance	:	Salbutamol
Indication:	:	Bronchodilator
Route of Administration	:	Inhalant

Schedule 3

ANNEXURE 1F: EMERGENCY CARE ASSISTANT

EMERGENCY CARE ASSISTANT registered with Health Professions Council of South Africa

EMERGENCY CARE ASSISTANT registered with Health Professions Council of South Africa
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Dextran Indication : Plasma expanders Route of Administration : Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Hydroxyethyl Starch Indication : Plasma expanders Route of Administration : Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Sodium chloride Indication : Plasma expanders Route of Administration : Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Ringers Lactate Indication : Plasma expanders Route of Administration : Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Polygeline Indication : Plasma expanders Route of Administration : Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Balanced Salt Solution Indication : Plasma expanders Route of Administration : Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Sodium Bicarbonate 8.5 % Indication : Metabolic acidosis Route of Administration : Parenteral

Schedule 3

CARBOHYDRATES		
Substance	:	Dextrose
Indication	:	Nutrition / Acute Symptomatic Hypoglycaemic Treatment in adults and paediatrics
Route of Administration	:	Parenteral
*CO-ENZYME		
Substance	:	Thiamine (Vitamin B1)
Indication	:	Nutritional supplement/ Vitamin B (Emergency treatment of Wernicke's encephalopathy and Beriberi).
Route of Administration	:	Parenteral
OTHER MINERAL SUPPLEMENTS		
Substance	:	Magnesium sulphate
Indication	:	Mineral supplement; prevention and control of seizures and hypertension in toxaemia of pregnancy
Route of Administration	:	Parenteral
SELECTIVE β2 AGONISTS		
Substance	:	Salbutamol
Indication:	:	Bronchodilator
Route of Administration	:	Inhalant

ANNEXURE 4: PODIATRIST

PODIATRIST [(B.Tech degree in Podiatry)] registered with the Health Professions Council of South Africa in terms of the Health Professions Act, 1974 (Act 56 of 1974)

– END SCHEDULE 3 –

SCHEDULE 4

a. All substances referred to in this Schedule are excluded when specifically packed, labelled, sold and used for –

(i) industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose; and

(ii) analytical laboratory purposes.

b. All preparations of substances or mixtures of such substances containing or purporting to contain any substance referred to in this Schedule and includes the following:

(ii) The salts and esters of such substances, where the existence of such salts and esters is possible; and

(iii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.

c. In terms of section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974 (Act 56 of 1974) other than a medical practitioner or dentist may prescribe and supply, only within his/her scope of practice and subject to the indication for use of such substances and medicines and to the conditions determined by the Authority, to patients under his/her care, the Schedule 4 substances and medicines provided for in the Annexures to this Schedule published in the Gazette in terms of the Act.

(i)	Annexure 1A:	Emergency Care Provider (Paramedic);
	Annexure 1B:	Emergency Care Provider (Emergency Care Practitioner);
	Annexure 1C:	Basic Ambulance Assistant
	Annexure 1D:	Ambulance Emergency Assistant
	Annexure 1E:	Emergency Care Technician
	Annexure 1F:	Emergency Care Assistant
(ii)	Annexure 2:	Dental Therapist;
(iii)	Annexure 3:	Optometrist.
(iv)	Annexure 4:	Podiatrist

Abemaciclib.

Acalabrutinib.

Arsenic:

a. when intended for injection;

b. except in oral dosage form. (S1, S2)

Schedule 4

Atezolizumab.

Baloxavir.

Baricitinib.

Benralizumab.

Besifloxacin.

Brolucizumab.

Carglumic.

Crisaborole.

Crisanlizumab.

Dimethyl fumarate.

Doxycycline, except

a. when intended and labelled for the chemoprophylaxis of malaria in those aged 8 years and older **[for periods not exceeding 4 months of continuous use].** (S2)

b. in preparations thereof for the treatment of animals and registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947).

Doravirine.

Durvalumab.

Erenumab.

Flurbiprofen,

a. when intended for ophthalmic use; (S4)
b. except when in the form of lozenges, indicated for the relief of pain associated with sore throats, subject to:
   (i) a maximum of 8,75 milligrams per lozenge;
   (ii) a maximum treatment period of 3 days; and
   (iii) a maximum pack size of 15 lozenges. (S1)
c. except when intended for application to the skin, provided that in the case of application by transdermal patch:
   (i) use is restricted to adults and children 12 years and older; and
   (ii) the treatment period is limited to a maximum of 4 weeks. **[(S1)]** (S0)
d. except when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days; (S2)

Schedule 4

Follitropin delta.

Frovatriptan.

Galcanezumab.

Human normal immunoglobulin.

Lenvatinib.

Lokivetmab.

Ranolazine.

Saroglitazar magnesium.

Semaglutide.

Simoctogog alfa.

Siponimod.

ANNEXURE 1A: EMERGENCY CARE PROVIDER (PARAMEDIC)

PARAMEDIC (National Diploma in Emergency Medical Care graduates ***only***) registered with the Health Professions Council of South Africa

PARAMEDIC (National Diploma in Emergency Medical Care graduates)		
*ANTI-FIBRINOLYTIC		
Substance	:	Tranexamic acid
Indication	:	Major haemorrhage in trauma
Route of Administration	:	Parenteral
**OXYTOCIN		
Substance	:	Oxytocin
Indication	:	Post-partum haemorrhage
Route of Administration	:	Parenteral
CORTICOSTEROID		
Substance	:	Prednisolone
Indication	:	Glucocorticoid/ Steroidal anti-inflammatory
Route of Administration	:	Parenteral
LOCAL ANAESTHETIC		
Substance	:	Lignocaine hydrochloride
Indication	:	Local anaesthesia
Route of Administration	:	Parenteral

Schedule 4

ANNEXURE 1B: EMERGENCY CARE PROVIDER (EMERGENCY CARE PRACTITIONER)

EMERGENCY CARE PRACTITIONER

(Bachelor of Technology Degree in Emergency Medical Care) registered with the Health Professions Council of South Africa

EMERGENCY CARE PRACTITIONER (B Tech: Emergency Medical Care)
**CORTICOSTEROID Substance : Betamethasone Indication : Pre-term birth Route of Administration : Parenteral
**CORTICOSTEROID Substance : Dexamethasone Indication : Pre-term birth Route of Administration : Parenteral
**DIRECT THROMBIN INHIBITOR Substance : Bivalirudin Indication : Adjunct in percutaneous coronary angioplasty Route of Administration : Parenteral
**DOPAMINERGIC Substance : Dopamine Indication : Haemodynamic support Route of Administration : Parenteral
**ADRENERGIC Substance : Dobutamine Indication : Haemodynamic support Route of Administration : Parenteral
*ANTICHOLINESTERASE Substance : Neostigmine Indication : Reversal of neuromuscular blockade Route of Administration : Parenteral
*CHOLINESTERASE INHIBITOR Substance : Sugammadex Indication : Reversal of neuromuscular blockade Route of Administration : Parenteral
*SEROTONIN ANTAGONIST Substance : Ondansetron Indication : Post-operative nausea and vomiting Route of Administration : Parenteral

Schedule 4

EMERGENCY CARE PRACTITIONER (B Tech: Emergency Medical Care)		
*ANTI-FIBRINOLYTIC		
Substance	:	Tranexamic acid
Indication	:	Major haemorrhage in trauma
Route of Administration	:	Parenteral
OXYTOCIN		
Substance	:	Oxytocin
Indication	:	Post-partum haemorrhage
Route of Administration	:	Parenteral
CORTICOSTEROID		
Substance	:	Prednisolone
Indication	:	Glucocorticoid/ Steroidal anti-inflammatory
Route of Administration	:	Parenteral
LOCAL ANAESTHETIC		
Substance	:	Lignocaine hydrochloride
Indication	:	Local anaesthesia
Route of Administration	:	Parenteral

ANNEXURE 1C: BASIC AMBULANCE ASSISTANT

BASIC AMBULANCE ASSISTANT registered with Health Professions Council of South Africa

BASIC AMBULANCE ASSISTANT registered with Health Professions Council of South Africa		
*SELECTIVE β2 AGONISTS		
Substance	:	Fenoterol
Indication	:	Bronchodilator
Route of Administration	:	Parenteral

Schedule 4

ANNEXURE 1D: AMBULANCE EMERGENCY ASSISTANT

AMBULANCE EMERGENCY ASSISTANT registered with Health Professions Council of South Africa

AMBULANCE EMERGENCY ASSISTANT registered with Health Professions Council of South Africa		
*ADRENERGIC		
Substance	:	Adrenaline / Epinephrine
Indication	:	Sympathomimetic catecholamine
Route of Administration	:	Parenteral
*CORTICOSTEROIDS		
Substance	:	Methylprednisolone
Indication	:	Glucocorticoid / Steroidal Anti-Inflammatory
Route of Administration	:	Oral
*CORTICOSTEROIDS		
Substance	:	Hydrocortisone
Indication	:	Glucocorticoid / Steroidal Anti-Inflammatory
Route of Administration	:	Parenteral
*HYPERGLYCAEMIC AGENT		
Substance	:	Glucagon
Indication	:	Hyperglycaemic agent
Route of Administration	:	Parenteral
*OPIOID ANTAGONIST		
Substance	:	Naloxone hydrochloride
Indication	:	Opioid Antagonist / Narcotic Antagonist
Route of Administration	:	Parenteral
OPIOID ANTAGONIST		
Substance	:	Nitrous oxide
Indication	:	Analgesic Gas
Route of Administration	:	Inhalant (50:50 combination with Medical Oxygen)
SELECTIVE β2 AGONISTS		
Substance	:	Fenoterol
Indication	:	Bronchodilator
Route of Administration	:	Parenteral
LOCAL ANAESTHETIC		
Substance	:	Lignocaine hydrochloride
Indication	:	Local anaesthesia
Route of Administration	:	Parenteral

Schedule 4

ANNEXURE 1E: EMERGENCY CARE TECHNICIAN

EMERGENCY CARE TECHNICIAN registered with Health Professions Council of South Africa

EMERGENCY CARE TECHNICIAN registered with Health Professions Council of South Africa		
ADRENERGIC		
Substance	:	Adrenaline / Epinephrine
Indication	:	Sympathomimetic catecholamine
Route of Administration	:	Parenteral
CORTICOSTEROIDS		
Substance	:	Methylprednisolone
Indication	:	Glucocorticoid / Steroidal Anti-Inflammatory
Route of Administration	:	Oral
CORTICOSTEROIDS		
Substance	:	Hydrocortisone
Indication	:	Glucocorticoid / Steroidal Anti-Inflammatory
Route of Administration	:	Parenteral
HYPERGLYCAEMIC AGENT		
Substance	:	Glucagon
Indication	:	Hyperglycaemic agent
Route of Administration	:	Parenteral
ANTI-ARRHYTHMICS		
Substance	:	Amiodarone
Indication	:	Class III Anti-arrhythmic / Atrial & Ventricular
Route of Administration	:	Parenteral
*ANTI-EMETIC		
Substance	:	Metoclopramide monohydrochloride
Indication	:	Propulsive Anti-emetic / Dopamine Antagonist
Route of Administration	:	Parenteral
SELECTIVE β2 AGONISTS		
Substance	:	Salbutamol
Indication:	:	Bronchodilator
Route of Administration	:	Parenteral
SELECTIVE β2 AGONISTS		
Substance	:	Fenoterol
Indication	:	Bronchodilator
Route of Administration	:	Parenteral

Schedule 4

ANTI-CHOLINERGIC		
Substance	:	Atropine
Indication	:	Competitive Anti-Cholinergic, Bradycardia, Anti-arrhythmic
Route of Administration	:	Parenteral
OPIOID ANTAGONIST		
Substance	:	Naloxone hydrochloride
Indication	:	Opioid Antagonist / Narcotic Antagonist
Route of Administration	:	Parenteral
OPIOID ANTAGONIST		
Substance	:	Nitrous oxide
Indication	:	Analgesic Gas
Route of Administration	:	Inhalant (50:50 combination with Medical Oxygen)
**OXYTOCIN		
Substance	:	Oxytocin
Indication	:	Post-partum haemorrhage
Route of Administration	:	Parenteral
CORTICOSTEROID		
Substance	:	Prednisolone
Indication	:	Glucocorticoid/ Steroidal anti-inflammatory
Route of Administration	:	Parenteral
LOCAL ANAESTHETIC		
Substance	:	Lignocaine hydrochloride
Indication	:	Local anaesthesia
Route of Administration	:	Parenteral

ANNEXURE 1F: EMERGENCY CARE ASSISTANT

EMERGENCY CARE ASSISTANT registered with Health Professions Council of South Africa

EMERGENCY CARE ASSISTANT registered with Health Professions Council of South Africa		
*ADRENERGIC		
Substance	:	Adrenaline / Epinephrine
Indication	:	Sympathomimetic catecholamine
Route of Administration	:	Parenteral

Schedule 4

CORTICOSTEROIDS		
Substance	:	Methylprednisolone
Indication	:	Glucocorticoid / Steroidal Anti-Inflammatory
Route of Administration	:	Oral
CORTICOSTEROIDS		
Substance	:	Hydrocortisone
Indication	:	Glucocorticoid / Steroidal Anti-Inflammatory
Route of Administration	:	Parenteral
HYPERGLYCAEMIC AGENT		
Substance	:	Glucagon
Indication	:	Hyperglycaemic agent
Route of Administration	:	Parenteral
ANTI-CHOLINERGIC		
Substance	:	Atropine
Indication	:	Competitive Anti-Cholinergic, Bradycardia, Anti-arrhythmic
Route of Administration	:	Parenteral
OPIOID ANTAGONIST		
Substance	:	Naloxone hydrochloride
Indication	:	Opioid Antagonist / Narcotic Antagonist
Route of Administration	:	Parenteral
OPIOID ANTAGONIST		
Substance	:	Nitrous oxide
Indication	:	Analgesic Gas
Route of Administration	:	Inhalant (50:50 combination with Medical Oxygen)
SELECTIVE β2 AGONISTS		
Substance	:	Fenoterol
Indication	:	Bronchodilator
Route of Administration	:	Parenteral

ANNEXURE 4: PODIATRIST

PODIATRIST [(B.Tech degree in Podiatry)] registered with the Health Professions Council of South Africa in terms of the Health Professions Act, 1974 (Act 56 of 1974)

– END SCHEDULE 4 –

SCHEDULE 5 AND SPECIFIED SCHEDULE 5

a. All preparations or mixtures of such substances containing or purporting to contain substances that is chemically related and incorporates a structural fragment into its structure that is similar to the structure of a listed substance and /or exhibits pharmacodynamic properties similar to the listed substance referred to in this Schedule include the following:

   (i) The salts and esters of such substances, where the existence of such salts and esters is possible; and

   (ii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.

   (iii) all homologues of listed substances (being any chemically related substances that incorporate a structural fragment into their structures that is similar to the structure of a listed substance and/or exhibit pharmacodynamic properties similar to the listed substance in the schedules), unless listed separately in the Schedules.

b. In terms of Section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974, other than a medical practitioner or dentist, may prescribe and apply, only within his/her scope of practice and subject to the indication for use of such substances and medicines and to the conditions determined by the Medicines Control Council, to patients under his/her care, the Schedule 5 and Specified Schedule 5 substances and medicines provided for in the Annexures to this Schedule published in the *Gazette* in terms of the Act.

   (i) Annexure 1A: Emergency Care Provider (Paramedic);

   Annexure 1B: Emergency Care Provider (Emergency Care Practitioner),

   Annexure 1E: Emergency Care Technician

c. Specified Schedule 5 substances listed in this schedule are subject to additional control in terms of section 22A of the Act as required under the provisions of the 1971 Convention on Psychotropic Substances and are denoted by **

Armodafanil.

Recombinant human epidermal growth factor (rhEGF).

Schedule 5

ANNEXURE 1A: EMERGENCY CARE PROVIDER (PARAMEDIC)

PARAMEDIC (National Diploma in Emergency Medical Care graduates ***only***) registered with the Health Professions Council of South Africa

PARAMEDIC (National Diploma in Emergency Medical Care graduates)		
*INDUCTION AGENTS		
Substance	:	Ketamine
Indication	:	Analgesia
Route of Administration	:	Parenteral

ANNEXURE 1E: EMERGENCY CARE TECHNICIAN

EMERGENCY CARE TECHNICIAN registered with Health Professions Council of South Africa

EMERGENCY CARE TECHNICIAN registered with Health Professions Council of South Africa		
BENZODIAZEPINE DERIVATIVE		
Substance	:	Diazepam
Indication	:	Anti-convulsant/Sedative/Hypnotic
Route of Administration	:	Parenteral
*BENZODIAZEPINE DERIVATIVE		
Substance	:	Midazolam
Indication	:	Antic-convulsant/Sedative/Hypnotic
Route of Administration	:	Parenteral
*BENZODIAZEPINE DERIVATIVE		
Substance	:	Lorazepam
Indication	:	Anti-convulsant/Sedative/Hypnotic
Route of Administration	:	Parenteral
BENZODIAZEPINE ANTAGONIST		
Substance	:	Flumazenil
Indication	:	Benzodiazepine Antagonist
Route of Administration	:	Parenteral
NON-SELECTIVE ANTIHISTAMINE		
Substance	:	Promethazine
Indication	:	Antihistamine
Route of Administration	:	Parenteral

Schedule 5

EMERGENCY CARE ASSISTANT registered with Health Professions Council of South Africa		
BENZODIAZEPINE DERIVATIVE		
Substance	:	Diazepam
Indication	:	Anti-convulsant/Sedative/Hypnotic
Route of Administration	:	Parenteral
*BENZODIAZEPINE DERIVATIVE		
Substance	:	Midazolam
Indication	:	Antic-convulsant/Sedative/Hypnotic
Route of Administration	:	Parenteral
*BENZODIAZEPINE DERIVATIVE		
Substance	:	Lorazepam
Indication	:	Anti-convulsant/Sedative/Hypnotic
Route of Administration	:	Parenteral
BENZODIAZEPINE ANTAGONIST		
Substance	:	Flumazenil
Indication	:	Benzodiazepine Antagonist
Route of Administration	:	Parenteral

– END SCHEDULE 5 –

SCHEDULE 6

a. All preparations or mixtures of such substances containing or purporting to contain substances that is chemically related and incorporates a structural fragment into its structure that is similar to the structure of a listed substance and /or exhibits pharmacodynamic properties similar to the listed substance referred to in this Schedule include the following (unless expressly excluded or unless listed in another Schedule):

(i) the isomers of such substances, where the existence of such isomers is possible within the chemical designation;

(ii) the esters and ethers of such substances and of the isomers referred to in (i) as well as the isomers of such esters and ethers, where the existence of isomers of such esters or ethers is possible;

(iii) the salts of such substances and of the isomers referred to in (i), as well as the salts of the esters, ethers and isomers referred to in (ii), where the existence of such salts is possible;

(iv) the isomers of any of the salts referred to in (iii), where the existence of such isomers is possible;

(v) all preparations and mixtures of any of the above.

(vi) all homologues of listed substances (being any chemically related substances that incorporate a structural fragment into their structures that is similar to the structure of a listed substance and/or exhibit pharmacodynamic properties similar to the listed substance in the schedules), unless listed separately in the Schedules.

b. In terms of Section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974, other than a medical practitioner or dentist, may prescribe and supply, only within his/her scope of practice and subject to the indication for use of such substances and medicines and to the conditions determined by the Authority, to patients under his/her care, the Schedule 6 substances and medicines provided for in the Annexures to this Schedule published in the *Gazette* in terms of the Act.

(i) Annexure 1A: Emergency Care Provider (Paramedic);

Annexure 1B: Emergency Care Provider (Emergency Care Practitioner).

Annexure 1E: Emergency Care Technician

Dexamfetamine (Dexamphetamine) in medicines registered in terms of the Act and intended for the treatment of Attention-Deficit Hyperactivity Disorder. (S7)

Schedule 6

ANNEXURE 1A: EMERGENCY CARE PROVIDER (PARAMEDIC)

PARAMEDIC (National Diploma in Emergency Medical Care graduates ***only***) registered with the Health Professions Council of South Africa

PARAMEDIC (National Diploma in Emergency Medical Care graduates)		
**ANALGESIC		
Substance	:	Fentanyl
Indication	:	Opioid/ Narcotic
Route of Administration	:	Parenteral

ANNEXURE 1B: EMERGENCY CARE PROVIDER (EMERGENCY CARE PRACTITIONER)

EMERGENCY CARE PRACTITIONER

(Bachelor of Technology Degree in Emergency Medical Care) registered with the Health Professions Council of South Africa

EMERGENCY CARE PRACTITIONER (Bachelor of Technology Degree in Emergency Medical Care) registered with the Health Professions Council of South Africa		
ANALGESIC		
Substance	:	Fentanyl
Indication	:	Opioid/ Narcotic/ Induction of Anaesthesia
Route of Administration	:	Parenteral

ANNEXURE 1E: EMERGENCY CARE TECHNICIAN

EMERGENCY CARE TECHNICIAN registered with Health Professions Council of South Africa

EMERGENCY CARE TECHNICIAN registered with Health Professions Council of South Africa		
*ANALGESICS		
Substance	:	Morphine sulphate
Indication	:	Opioid/Narcotic
Route of Administration	:	Parenteral

SCHEDULE 7

All preparations or mixture of such substances containing or purporting to contain substances referred to in this Schedule include the following (unless expressly excluded or unless listed in another Schedule):

(i) the isomers of such substances, where the existence of such isomers is possible within the chemical designation;

(ii) the esters and ethers of such substances and of the isomers referred to in (i), as well as the isomers of such esters and ethers, where the existence of isomers of such esters, or ethers is possible;

(iii) the salts of such substances and of the isomers referred to in (i), as well as the salts of the esters, ethers and isomers referred to in (ii), where the existence of such salts is possible;

(iv) the isomers of any of the salts referred to in (iii), where the existence of such isomers is possible;

(v) all preparations and mixtures of any of the above.

(vi) all homologues of listed substances (being any chemically related substances that incorporate a structural fragment into their structures that is similar to the structure of a listed substance and/or exhibit pharmacodynamic properties similar to the listed substance in the schedules), unless listed separately in the Schedules.

Dexamfetamine (Dexamphetamine) except in medicines registered in terms of the Act and intended for the treatment of Attention-Deficit Hyperactivity Disorder (S6) **[and its salts; preparations thereof. (S8)]**

– END SCHEDULE 7 –

SCHEDULE 8

All preparations or mixture of such substances containing or purporting to contain substances referred to in this Schedule include the following (unless expressly excluded or unless listed in another Schedule):

(i) the isomers of such substances, where the existence of such isomers is possible within the chemical designation;

(ii) the esters and ethers of such substances and of the isomers referred to in (i), as well as the isomers of such esters and ethers, where the existence of such isomers of esters and ethers is possible;

(iii) the salts of such substances and of the isomers referred to in (i), as well as the salts of the esters, ethers and isomers referred to in (ii), where the existence of such salts is possible;

(iv) the isomers of any of the salts referred to in (iii), where the existence of such isomers is possible;

(v) all preparations and mixtures of any of the above.

[Dexamfetamine (Dexamphetamine) and it salts; preparations thereof. (S7)]

These Schedules as amended come into operation on the date of publication in the Government *Gazette*.

DR ZWELINI LAWRENCE MKHIZE, MP
MINISTER OF HEALTH
DATE: 23/11/2020

Printed by and obtainable from the Government Printer, Bosman Street, Private Bag X85, Pretoria, 0001
Contact Centre Tel: 012-748 6200. eMail: info.egazette@gpw.gov.za
Publications: Tel: (012) 748 6053, 748 6061, 748 6065

This gazette is also available free online at **www.gpwonline.co.za**